Ariëns LFM, van der Schaft J, Bakker DS, et al. - Using data from a prospective multicenter registry, the BioDay registry, researchers assessed clinical response as well as serum biomarkers following 16-week treatment with dupilumab among adult patients (n = 138) suffering from moderate-severe atopic dermatitis (AD) in daily practice. They assessed the number of patients reaching EASI-50 (Eczema Area and Severity Index) or EASI-75 and evaluated patient-reported outcomes measures. The study sample included patients with very difficult-to-treat AD; 84 (61%) patients had experienced treatment failure on ≥ 2 immunosuppressive drugs. The mean percent change in EASI score at week 16 was estimated to be 73%. Following 16 weeks of treatment, 114 (86%) and 82 (62%) patients achieved EASI-50 and EASI-75, respectively. In patients managed for very difficult-to-treat AD in a daily practice setting, a significant improvement in disease severity and reduction in severity-related serum biomarkers was brought about by treatment with dupilumab.